Advanced searches left 3/3

Soft Tissue Sarcoma - Europe PMC

Summarized by Plex Scholar
Last Updated: 20 June 2022

* If you want to update the article please login/register

Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study.

"Purpose Outcome for patients with metastatic rhabdomyosarcoma is poor. " This report presents the results of the MTS 2008 study with a pooled analysis including patients from the concurrent BERNIE study. Patients and methods In MTS 2008, patients with metastatic RMS were given four cycles of ifosfamide, vincristine, and actinomycin D plus doxorubicin, five cycles of IVA, and 12 cycles of maintenance chemotherapy. Patients were randomly assigned by the BERNIE study to the addition or not of bevacizumab to the same chemotherapy regimen. According to three generations of pooled research on 372 patients with a median follow-up of 55. 2 months, 3-year EFS and OS were 35. 5% and 49. 3%, respectively. Patients with u22642 2 Oberlin risk factors had better results than those with u2265 3 ORFs: 3-year EFS was 51% vs. 26. 0% versus 26. 0% versus 26. 0% versus 26. 0%. "Outcome for patients with metastatic RMS and multiple ORFs remains poor," says the author.

Source link: https://europepmc.org/article/MED/35709412


Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.

"Prosecutive genomic profiling could help with this challenge by providing insight into sarcomas' molecular causes. " We find a variety of recurrent and type-specific changes that support diagnosis and treatment decisions through targeted panel sequencing of 7494 sarcomas representing 44 histologies. Nearly one-third of patients have potentially harmful changes, with a significant number of kinase gene rearrangements; 3. 9% have a tumor mutational burden, with U226510 mut/Mb. Our results reveal the genetic landscape of human sarcomas, which may help with the discovery of new therapeutics and improving clinical outcomes for patients with these rare cancers.

Source link: https://europepmc.org/article/MED/35705558


Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study.

"Background Data from the actual-world setting on perioperative chemotherapy in sarcoma's high-risk, localized soft tissue sarcoma is limited. " Real-world reports include results obtained from patients enrolled outside of clinical trials, as well as a long-term follow-up that was not present in clinical trials. Participants in the research were selected from 1998 to 2017 for adult patients with localized STS in the extremities or trunk wall treated at Oslo University Hospital, Oslo, Norway. During a long-term follow-up, two patients developed secondary malignancies, cardiac toxicity was discovered in 11 patients, and renal toxicity in 12 patients. 5-year MFS in the RWD cohort was 53% and in the study cohort 61%, 61%. Long-term results after perioperative chemotherapy were comparable for patients treated in routine clinical practice to those in clinical trials. "Perioperative chemotherapy should include the possibility of severe late side effects, as well as the possibility of severe late side effects. ".

Source link: https://europepmc.org/article/MED/35698755


Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.

"Background Adolescent and young adult patients with rhabdomyosarcoma have poorer outcomes than do children. " We wanted to compare the results of adolescent and young adult patients with children who were enrolled in two prospective clinical trials. Methods This retrospective observation was based on findings from the European paediatric Soft tissue sarcoma 2005 trial and the EpSSG MTS 2008 project, which involved 108 centers from 14 different countries in total. Only patients with high risk localised rhabdomyosarcoma were included in the randomised portion of the randomized portion of the rhabdomyosarcoma 2005 study for the analysis of adherence to treatment and toxicity. The EpSSG rhabdomyosarcoma 2005 study featured 258 patients, while 258 patients were from the EPSSG MTS 2008 survey. Adolescent and young adult patients were more likely than male tumors, unfavorable histological subtypes, tumors larger than 5 cm, and regional lymph node involvement. Children had lower 5-year event-free survival and lower 5-year overall survival than those who did not. This research found improved outcomes for adolescent and young adult patients, with no major tolerability issues and should be included in paediatric rhabdomyosarcoma trials," according to the study.

Source link: https://europepmc.org/article/MED/35690071


Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma.

"Purpose To investigate the effectiveness and safety of TQB2450 combined with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma. " Embedded In patients with LA/M STS, this was a single arm phase II research carried out at two hospitals in China to determine the potency of TQB2450 combined with anlotinib. Patients had been resistant to at least one chemotherapy drug prior to being unresponsive to at least one chemotherapy drug. Anlotinib was given orally from day 1 to day 14 every three weeks. The median PFS was 7. 85 months [95% confidence interval 2. 89-23. 06] and the median OS was not reached, but it was not established. The ORR was 75% among the ASPS patients, and median PFS was 23. 06 months. Conclusions The study found the promising growth in patients with ASPS as well as the trend of treatment success in other sarcomas. "A newer research with a larger sample size and controlled arm were both encouraged. ".

Source link: https://europepmc.org/article/MED/35675031


Complex Elucidation of Cells-of-Origin in Pediatric Soft Tissue Sarcoma: From Concepts to Real Life, Hide-and-Seek through Epigenetic and Transcriptional Reprogramming.

"Soft tissue sarcoma" is a prominent group of mesenchymal malignant tumors with heterogeneous cellular morphology, proliferative index, genetic abnormalities, and, ultimately, clinical features. Here, we explore how cell reprogramming mediated by driver genes in STS can dramatically change the molecular and morphological characteristics of a transformed cell, leading to a erroneous interpretation of the cell's cell-of-origin. This study challenges the fact that the epigenetic environment in which a genetic mutation arises must be taken into account as a primary determinant of STS tumor initiation and progression. ".

Source link: https://europepmc.org/article/MED/35682989


Research on imbalance machine learning methods for MRT1WI soft tissue sarcoma data

"Pathological grading of the soft tissue sarcoma is a key factor in patient prognosis and treatment planning, but the clinical results of soft tissue sarcoma are inconsistent. " We present an effective way to find the most suitable imbalance machine learning scheme for predicting the classification of soft tissue sarcomas data in this paper. The receiver operating characteristic curve model is used to analyze these nine techniques for predicting the pathological grade of soft tissue sarcoma. Result: : The experimental results show that the combination of extremely random tree classification algorithm using random oversampling examples and the recursive feature elimination method is the most effective compared to other combination methods. The proposed machine learning technique can contribute to resolving the data classification issue, which may help ensure the creation of individual treatment plans for soft tissue sarcoma patients. ".

Source link: https://europepmc.org/article/PPR/PPR502445


Non-injection-site soft tissue sarcoma in cats: outcome following adjuvant radiotherapy.

"Objectives" Biological behavior and treatment options in cats that have non-injection-site soft tissue sarcomas are less well understood than in dogs. The aim of this retrospective study was to determine the effects of cats with nFIS following adjuvant radiotherapy-based care. Methods The medical records of cats with soft tissue sarcomas in places not related to, and histology studies not supportive of, injection-site sarcomas were analyzed. The overall median progression-free period for 17/18 cats with recurrence was 2748 days, while the median PFI for the 7/8 cats with recurrence was 164 days. Adjuvant radiotherapy resulted in good long-term tumour control in 12/18 cats with nFISS, which was conclusive and relevant. "Research in larger populations is required to determine the effect of multiple surgeries prior to the start of radiotherapy on outcomes," says researcher Robert Leibn.

Source link: https://europepmc.org/article/MED/35639367


Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcoma.

"Introduction" is a term that describes the use of definitive radiotherapy in unresectable soft-tissue sarcomas is still controversial, and latest reports are scarce. Methods We retrospectively included STS patients treated between 2009 and 2020, whether it was unresectable or with a persistent residual disease following R2 surgery. 116 patients with localized/locally advanced STS were treated from 2009 to 2020, with a median age of 71 years. 60 Gy was the average equivalent dose in two Gy fractions. At the first follow-up, 66 and 25 patients had stable disease with partial response. Following a median follow-up of 54. 8 months, 3-year LF, PFS, and OS, respectively, the results were 43. 2%, 16. 6%, and 34 percent. The multivariate analysis revealed that grade 3 and AJCC T3-T4 stage to be closely linked to shorter PFS and OS as a result of both shorter PFS and OS. Conclusion In unresectable STS patients, definitive radiotherapy is a safe and effective therapy that results in long-term monitoring in selected patients. ".

Source link: https://europepmc.org/article/MED/35640770


Detection of Soft Tissue Sarcoma Recurrence: Feasibility of Ultrafast 3D Gradient-Echo Sequence in Addition to Conventional Contrast-Enhanced MRI to Provide Early-Phase Postcontrast Information.

"Materials and methods" In this retrospective review, 297 patients under surgical surveillance for malignant STS were included in this retrospective research and divided into three subgroups, as follows: group A, recurrent tumors; group B, pseudomasses; and group C, postoperative inflammation. The results In the early stages, all mean CNR and SIR values were markedly higher in group A compared to group B. However, the difference in the CNR between early and delayed post-contrast MRI revealed a significantly smaller rise in group A than in the other groups when muscle was used as the reference tissue. A analysis of ROC curves revealed that dual-phase MRI had significantly higher diagnostic success than conventional postcontrast MRI. Conclusion "The addition of an early postcontrast 3D GRE to traditional FSE-T1WI is a useful way to spot recurrent tumors by giving more detail on early development. ".

Source link: https://europepmc.org/article/MED/35651919

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions